Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.3452W HIGH $5.07
Volume
169.70 K
Value Traded
82.52 K
Short % Float
2.06%
-21.35%Week
-40.8%1 Month
-50.35%3 Month
-49.28%6 Month
-99.26%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
13.23 M
EPS (TTM)
-2.36
P/E Ratio
-
Ent. Value
-20.76 M
Total Shares
9.45 M
Float Shares
9.29 M
Insiders
1.75%
Institutions
34.87%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
CLRB Catalyst Timeline
Dated clinical, regulatory and corporate events for Cellectar Biosciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cellectar Biosciences, Inc.
810Total events
12Upcoming
137Tier-1 (high impact)
2013 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Trial InitiationTrial
Site activation initiated for confirmatory Phase 3 study of iopofosine I 131 in WM
Waldenström macroglobulinemiasource ↗
▲PublicationPresentation
Published Phase 1 data of iopofosine I 131 in r/r MM in journal Cancer
multiple myelomasource ↗
▲Trial InitiationTrial
Initiated enrollment and dosing of first patients in Phase 1b trial of CLR 125 in TNBC
triple negative breast cancersource ↗
▲PublicationPresentation
Publication of Phase 1 study of iopofosine I 131 in Cancers
relapsed/refractory multiple myelomasource ↗
▲Poster PresentationPresentation
Presented CLOVER WaM data at ASCO 2026 Annual Meeting
Waldenström macroglobulinemiasource ↗
◆Interim AnalysisTrial
Interim data from Phase 1b study of CLR 125 for TNBC
Triple Negative Breast Cancersource ↗
◆Topline ReadoutClinical Data
Early data from Phase 1b CLR 125 study expected by mid-year 2026
Triple Negative Breast Cancersource ↗
▲Full ResultsClinical Data
Positive 12-month follow-on data for Iopofosine I 131 in r/r WM
relapsed/refractory Waldenström Macroglobulinemiasource ↗
▲Trial InitiationTrial
Dosed first patients in Phase 1b dose finding study for CLR 125 in TNBC
Triple Negative Breast Cancersource ↗
▼Equity OfferingCorporate
Closed registered direct offering and private placement raising $35M upfront
▲First Patient DosedTrial
First patient enrolled in Phase 1b trial of CLR 125 for TNBC
refractory triple negative breast cancersource ↗
◆Enrollment UpdateTrial
Additional study sites being activated in Q2 2026
refractory triple negative breast cancersource ↗
◆Timing GuidancePresentation
Early dosimetry, safety and efficacy data expected mid-year 2026
Triple Negative Breast Cancersource ↗
▲Patent GrantedIP / Competition
Broad expansion of global intellectual property estate including newly issued patents across Europe, Asia-Pacific, Middle East, and Americas
◆Oral PresentationPresentation
Corporate update at Biotech Showcase during JP Morgan Healthcare Conference
▲First Patient DosedTrial
Dosing of first patients in Phase 1b study of CLR 125 for TNBC
Triple Negative Breast Cancersource ↗
▲Partnership / LicenseCorporate
Multi-year supply agreement with Ionetix for Ac-225 and At-211
▲Trial InitiationTrial
Initiated Phase 1b study of CLR 125 for TNBC
Triple-negative breast cancer (TNBC)source ↗
▲Rare Pediatric DiseaseDesignation
Received Rare Pediatric Drug Designation for iopofosine I 131 in r/r pHGG
Inoperable relapsed/refractory pediatric high-grade glioma (r/r pHGG)source ↗
▲Rare Pediatric DiseaseDesignation
FDA grants Rare Pediatric Disease Designation for iopofosine I 131 in r/r pHGG
relapsed or refractory pediatric high-grade gliomasource ↗
●IND Enabling CompletePreclinical
CLR 225 completed IND-enabling studies
pancreatic ductal adenocarcinoma (PDAC)source ↗
▲EU MAA SubmissionEx-US Regulatory
EMA SAWP confirms eligibility to file for CMA
Refractory (post-BTKi) Waldenstrom macroglobulinemia (WM)source ↗
▲Trial InitiationTrial
Phase 1b clinical trial initiation for CLR 125 in TNBC
Triple-Negative Breast Cancersource ↗
●Enrollment UpdateTrial
CLOVER-2 study active but not enrolling
relapsed or refractory pediatric high-grade gliomasource ↗
◆Poster PresentationPresentation
AACR Special Conference: Targeting Lipid Rafts in Hypoxic Pancreatic Ductal Adenocarcinoma: Preclinical Evaluation of [225Ac]CLR 121225, a Novel Actinium-Based Radio-Conjugate
pancreatic ductal adenocarcinomasource ↗
▲Poster PresentationPresentation
Poster presentation of preclinical data for CLR 225 at AACR Special Conference on Pancreatic Cancer Research
pancreatic ductal adenocarcinoma (PDAC)source ↗
◆Oral PresentationPresentation
Oral presentation of interim data from Phase 1b CLOVER-2 trial at AACR Special Conference on Pediatric Cancer
inoperable relapsed or refractory pediatric high-grade gliomasource ↗
◆Oral PresentationPresentation
Oral presentation of interim data from Phase 1b CLOVER-2 study at AACR Special Conference on Pediatric Cancer
inoperable relapsed or refractory pediatric high-grade gliomasource ↗
◆Interim AnalysisTrial
Interim data from Phase 1b CLOVER-2 study presented at AACR conference
inoperable relapsed or refractory pediatric high-grade gliomasource ↗
▲Partnership / LicenseCorporate
Cellectar and Evestia Clinical announce partnership for Phase 1b trial of CLR 125 in TNBC
◆Oral PresentationPresentation
Targeted Radiopharmaceuticals Supply Chain and Manufacturing: Addressing Facility Downtime & Regulatory Delays by Designing Robust Infrastructure Strategy to Accelerate Safe, Scalable Radiopharmaceutical Manufacturing
◆Oral PresentationPresentation
BioProcess International: ADCs and Beyond in Radiopharmaceuticals
▲Preclinical PoCPreclinical
CLR 121225 demonstrated anti-tumor effects in preclinical studies
solid tumors, including pancreatic cancersource ↗
◆Oral PresentationPresentation
Cellectar management participation at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
◆Oral PresentationPresentation
ADC and Novel Conjugates Partnering and Investment Summit: ADCs x Radioligands: The Use of One Technology to Advance the Other
◆Oral PresentationPresentation
Oral presentation of interim data from CLOVER-2 at AACR Special Conference on Pediatric Cancer
relapsed or refractory pediatric high-grade gliomasource ↗
◆EU MAA SubmissionEx-US Regulatory
EMA decision on potential conditional marketing authorization submission for iopofosine I 131 in WM
Waldenstrom Macroglobulinemiasource ↗
▲Breakthrough Therapy DesignationDesignation
FDA Breakthrough Therapy Designation for iopofosine I 131 in WM
Waldenstrom Macroglobulinemiasource ↗
▼Equity OfferingCorporate
Closing of $6.9 million underwritten public offering with full exercise of over-allotment option
Past FDA Catalysts and PDUFA Decisions
How CLRB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-11-13 | CLR 125 | IND Clearance | IND |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C51 / 100
Pipeline Score
$18M
Pipeline Value
Fair Value
Valuation Signal
4
Drugs Scored
1.1x
rNPV / MCap
Top 16%
Micro Cap(rank 106 of 658)
Percentile Rank
Cellectar Biosciences, Inc. carries a moderate pipeline score (51/100), with $1.5B risk-adjusted pipeline value, led by I-131-CLR1404 in Multiple Myeloma (Phase 1), across $64B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I-131-CLR1404 Small moleculeCompletedNCT02278315 | Multiple Myeloma | Phase 1 | COMPLETED | 31 | Aug 10, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every CLRB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| iopofosine I 131 BreakthroughFast TrackAccelerated+2 | Waldenström Macroglobulinemia | Phase 2 | 2026-09-29 | Major Response Rate of 79.2%; Overall Response Rate of 87.5%; Duration of Response Exceeding 16 MonthsRead More | Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström MacroglobulinemiaRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Loren StefanConsultant | Grant/Award | 15,000 15,000 held | $0.00 | 07/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CLRB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SILVERARC CAPITAL MANAGEMENT, LLC | 0.1 % | 894.00 K | 321.73 K |
CLRB Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CLRB ranks across every disease it competes in
Competitive Position is a premium feature
See how CLRB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCLRB News
CLRBCellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia
Cellectar Biosciences announced promising efficacy data from a subset analysis of its Phase 2 CLOVER WaM trial for iopofosine I 131, targeting Waldenströms Macroglobulinemia patients resistant to BTK inhibitors. The data, showing a major response rate of 79.2%, will be presented at the International Workshop for Waldenströms Macroglobulinemia. The company plans to advance to a Phase 3 trial and seek accelerated approval in early 2027.
Read more →CLRBCellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Cellectar Biosciences reported its financial results for Q2 2026, highlighting significant advancements in its oncology pipeline. The company initiated a Phase 3 study for iopofosine I 131 and presented promising data from the CLOVER WaM trial at ASCO. Additionally, enrollment for the Phase 1b trial of CLR 125 in triple-negative breast cancer has begun. Financially, Cellectar's cash reserves have improved, supporting its ongoing research efforts.
Read more →CLRBCellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026
Cellectar Biosciences will report its second quarter financial results on August 13, 2026, at 8:30 a.m. ET. The company focuses on developing cancer treatments using its Phospholipid Drug Conjugate delivery platform. Its lead product, iopofosine I 131, has received several FDA designations and is being tested in various cancer indications, while CLR 125 is in Phase 1b trials for triple negative breast cancer.
Read more →CLRBCellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers
Cellectar Biosciences announced the publication of a Phase 1 study on iopofosine I 131, which showed promising safety and preliminary efficacy in patients with relapsed/refractory multiple myeloma. The study, published in the journal Cancers, indicated a significant response rate and manageable adverse effects, supporting further development of this targeted radiotherapeutic. The findings suggest potential applications across various B-cell malignancies.
Read more →CLRB▼ -5.4%on this news
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
Cellectar Biosciences announced promising efficacy data from its Phase 2 CLOVER WaM study of iopofosine I 131 for treating relapsed or refractory Waldenström macroglobulinemia. The study reported a major response rate of 79.2% and a median duration of response of 16 months. The company plans to initiate a Phase 3 confirmatory trial in Q4 2026, aiming for accelerated approval in the U.S.
Read more →CLRB▲ +8.8%on this news
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Cellectar Biosciences has reported its financial results for the first quarter of 2026, highlighting significant progress in its clinical pipeline. The company secured up to $140 million in financing to support advancements in their lead compound, iopofosine I 131, for the treatment of relapsed/refractory Waldenström macroglobulinemia. Recent follow-up data from the CLOVER-WaM study indicated promising efficacy and will support a Phase 3 study. Additionally, Cellectar has initiated a Phase 1b trial for CLR 125 in triple-negative breast cancer, emphasizing their commitment to developing innovative cancer therapies.
Read more →CLRBCellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
Cellectar Biosciences will report its first quarter financial results on May 14, 2026, at 8:30 a.m. ET. The company focuses on developing cancer treatments using its proprietary Phospholipid Drug Conjugate platform. Its lead product, iopofosine I 131, has received several FDA designations and is currently in various clinical trials. CLR 125 is also being evaluated for solid tumors, showing promising preclinical data.
Read more →CLRB▲ +12.4%on this news
Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million
Cellectar Biosciences announced an oversubscribed financing round totaling up to $140 million, aimed at supporting a confirmatory study and NDA filing for its drug, Iopofosine I 131, targeting Waldenström macroglobulinemia. The financing was led by Nantahala Capital Management with backing from other notable institutional investors and will enhance Cellectar's ability to advance its proprietary drug conjugate delivery platform. Following the financing close, Andrew Gu from Nantahala will join the company’s Board of Directors. The initiative underscores investor confidence in Cellectar's treatment options for unmet medical needs in oncology.
Read more →CLRBCellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026
Cellectar Biosciences announced that an abstract detailing subset data from their CLOVER WaM clinical trial has been accepted for presentation at the American Society of Clinical Oncology Annual Meeting in June 2026. This data focuses on the treatment of relapsed or refractory Waldenström's Macroglobulinemia (WM) patients, highlighting the significant unmet medical need in this population. The company emphasizes the encouraging safety and efficacy results for its investigational drug, iopofosine I-131, which may provide new therapeutic options for patients who have already progressed on BTK inhibitors.
Read more →CLRB▲ +7.7%on this news
Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)
Cellectar Biosciences announced the enrollment of the first patient in a Phase 1b clinical trial for CLR 125, a radioconjugate aimed at treating refractory triple negative breast cancer (TNBC). CLR 125 utilizes an Auger-emitting platform to deliver targeted cytotoxic radiation to tumor cells. Initial preclinical studies suggest that CLR 125 has effective tumor-targeting characteristics and minimal systemic toxicity. The trial aims to assess safety, tolerability, and preliminary efficacy across different dosing regimens.
Read more →CLRB▲ +8.2%on this news
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
Cellectar Biosciences reported its financial results for 2025, highlighting significant progress in its clinical pipeline. The company is preparing to submit a Conditional Marketing Authorization for iopofosine I-131 in Europe and has initiated a Phase 1b study for CLR 125 in Triple Negative Breast Cancer. Despite a net loss of $21.8 million, Cellectar remains optimistic about its future prospects and ongoing clinical developments.
Read more →CLRBCellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026
Cellectar Biosciences, Inc. will report its full year financial results for 2025 and provide a corporate update on March 4, 2026. The company focuses on developing cancer treatments using its proprietary Phospholipid Drug Conjugate delivery platform. Its lead product, iopofosine I 131, has received several FDA designations, highlighting its potential in treating various cancers.
Read more →CLRB▼ -5.2%on this news
Cellectar Biosciences Expands Global Intellectual Property Estate
Cellectar Biosciences has expanded its global intellectual property estate, securing new patents across multiple regions. This expansion enhances protection for its cancer-targeting drug, iopofosine I 131, as the company prepares for a conditional marketing approval filing with the EMA for Waldenström macroglobulinemia. The CEO highlighted the importance of this development for their long-term strategy and commitment to improving treatment options for patients.
Read more →CLRB▼ -6.9%on this news
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference
Cellectar Biosciences will present its strategic initiatives for 2026 at the Biotech Showcase during the JP Morgan Healthcare Conference. The company aims to submit for conditional marketing approval of iopofosine I 131 for Waldenstrom’s Macroglobulinemia in Europe by Q3 2026. Additionally, they plan to initiate a Phase 1b study for CLR 125 targeting triple negative breast cancer in early 2026.
Read more →CLRBCellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
Cellectar Biosciences has entered a multi-year supply agreement with Ionetix for Actinium-225 and Astatine-211, essential radioisotopes for advancing its targeted alpha therapy programs. This partnership aims to support Cellectar in clinical trials and potential commercial launches of its therapies for solid tumors like pancreatic cancer. Ionetix is enhancing its production capabilities with additional cyclotrons to meet the growing demand for these isotopes. The collaboration is poised to strengthen Cellectar's ability to deliver innovative cancer treatments.
Read more →CLRB▼ -18%on this news
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Cellectar Biosciences reported its third quarter 2025 financial results, highlighting significant advancements in its drug development pipeline. The company expects to submit a conditional marketing approval application for iopofosine I 131 in Europe in 2026 and has initiated a Phase 1b study for CLR 125. Additionally, iopofosine I 131 has received multiple FDA designations, reinforcing its potential in treating various cancers.
Read more →CLRBCellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025
Cellectar Biosciences, Inc. will report its financial results for the third quarter ended September 30, 2025, and provide a corporate update on November 13, 2025. The company specializes in developing drugs for cancer treatment using its proprietary Phospholipid Drug Conjugate delivery platform. Their lead asset, iopofosine I 131, has received several designations from the FDA aimed at accelerating its development for various cancer indications.
Read more →CLRB▼ -10.3%on this news
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
Cellectar Biosciences has received Rare Pediatric Disease Designation from the FDA for iopofosine I 131, aimed at treating relapsed or refractory pediatric high-grade glioma. The designation highlights the drug's potential to address a severe pediatric cancer. Interim results from the CLOVER-2 trial indicate significant improvements in progression-free and overall survival among patients. The company is optimistic about further development and collaboration opportunities.
Read more →CLRBCellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
Cellectar Biosciences presented promising preclinical data for CLR 225 at the AACR Special Conference. The data highlighted CLR 225's effectiveness in targeting pancreatic ductal adenocarcinoma, showcasing its anti-tumor activity and safety profile. The findings support advancing CLR 225 into Phase 1 studies, aiming to improve treatment outcomes for pancreatic cancer patients.
Read more →CLRB▼ -16.9%on this news
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million
Cellectar Biosciences, Inc. has entered agreements with institutional investors to raise approximately $5.8 million by exercising existing warrants. The funds will be utilized for working capital, a Phase 1b clinical study of CLR 121125 in triple-negative breast cancer, and preparing for a Conditional Marketing Authorization with the EMA. The company continues to advance its innovative cancer treatment pipeline.
Read more →About Cellectar Biosciences, Inc.
Headquarters100 CAMPUS DRIVE, FLORHAM PARK, NJ, 07932
BIOPHARMAWATCH ELITE PLUS
Trade the next CLRB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime